Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02444533 · ClinicalTrials.gov registry record · Phase 4
EXPAREL® for Pain After Tonsillectomy
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
NCT02444533: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT02444533 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02444533, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether liposomal bupivacaine (long acting injectable anesthetic) provides greater post operative pain relief compared to the standard post operative pain regiment for tonsillectomy patients.
Interventions
- DRUG Liposomal Bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02444533
The ClinicalTrials.gov registry entry for NCT02444533 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Liposomal Bupivacaine is the first listed.
NCT02444533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02444533 about?
NCT02444533 is a clinical study titled "EXPAREL® for Pain After Tonsillectomy". The purpose of this study is to determine whether liposomal bupivacaine (long acting injectable anesthetic) provides greater post operative pain relief compared to the standard post operative pain regiment for tonsillectomy patients.
What is the current status of trial NCT02444533?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2015-05. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02444533?
The interventions under investigation include: Liposomal Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT02444533?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.